Literature DB >> 10583291

Improved management of infrainguinal bypass graft infection with methicillin-resistant Staphylococcus aureus.

R T Chalmers1, J H Wolfe, N J Cheshire, G Stansby, A N Nicolaides, A O Mansfield, S P Barrett.   

Abstract

BACKGROUND: There is considerable debate over the management of infected infrainguinal grafts. This report describes recent experience in this field and documents the change in clinical practice needed to deal with methicillin-resistant Staphylococcus aureus (MRSA).
METHODS: All infected infrainguinal grafts between January 1991 and July 1997 were reviewed. In the light of the findings, clinical practice was modified considerably. A further 1 year was audited prospectively up to August 1998.
RESULTS: Twenty-six patients were treated for 27 infrainguinal graft infections (25 prosthetic, two vein). Twenty were treated by complete graft excision as the initial therapy; graft preservation was attempted in six patients. Before 1995, the infecting organisms were predominantly Pseudomonas aeruginosa or methicillin-sensitive staphylococci. Subsequently all 14 patients treated up to 1997 had infection with MRSA. The overall amputation rate was 17 of 26; ten amputations were in patients with MRSA. Four patients died, all with MRSA sepsis. As a result of this experience a policy of complete isolation was adopted for all patients infected with MRSA. In the 12 months since this policy was introduced, 77 infrainguinal grafts (61 vein, 16 prosthetic) have been inserted. Two grafts (3 per cent) have become infected, necessitating graft excision and amputation.
CONCLUSION: MRSA infection of an infrainguinal graft is a serious complication with high associated amputation and mortality rates. Isolation and barrier nursing appeared to contain the problem.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10583291     DOI: 10.1046/j.1365-2168.1999.01267.x

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  7 in total

1.  Methicillin-resistant Staphylococcus aureus infection in vascular surgical patients.

Authors:  G J Murphy; R Pararajasingam; A Nasim; M J Dennis; R D Sayers
Journal:  Ann R Coll Surg Engl       Date:  2001-05       Impact factor: 1.891

2.  Should vascular surgery patients be screened preoperatively for methicillin-resistant Staphylococcus aureus?

Authors:  Bruce Y Lee; Becky Y Tsui; Rachel R Bailey; Kenneth J Smith; Robert R Muder; G Jonathan Lewis; Lee H Harrison
Journal:  Infect Control Hosp Epidemiol       Date:  2009-12       Impact factor: 3.254

3.  Surgical and antimicrobial treatment of prosthetic vascular graft infections at different surgical sites: a retrospective study of treatment outcomes.

Authors:  Stefan Erb; Jan A Sidler; Luigia Elzi; Lorenz Gurke; Manuel Battegay; Andreas F Widmer; Maja Weisser
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

4.  Complex treatment of vascular prostheses infections.

Authors:  Octavian Andercou; Dorin Marian; Gabriel Olteanu; Bogdan Stancu; Beatrix Cucuruz; Thomas Noppeney
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

5.  Prosthetic vascular graft infection: a multi-center review of surgical management.

Authors:  Eleonore Zetrenne; Bryan C McIntosh; Mark H McRae; Richard Gusberg; Gregory R D Evans; Deepak Narayan
Journal:  Yale J Biol Med       Date:  2007-09

6.  Salvage of Exposed Groin Vascular Grafts with Early Intervention Using Local Muscle Flaps.

Authors:  Brian L May; Nicole A Zelenski; Sanjay V Daluvoy; Matthew W Blanton; Cynthia K Shortell; Detlev Erdmann
Journal:  Plast Reconstr Surg Glob Open       Date:  2015-09-22

7.  Factors predictive of treatment failure in staphylococcal prosthetic vascular graft infections: a prospective observational cohort study: impact of rifampin.

Authors:  Laurence Legout; Piervito Delia; Béatrice Sarraz-Bournet; Cécile Rouyer; Massongo Massongo; Michel Valette; Olivier Leroy; Stephan Haulon; Eric Senneville
Journal:  BMC Infect Dis       Date:  2014-04-28       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.